Drug Search Results
Using advanced filters...
Advanced Search [+]

Adrenomedullin

Alternative Names: adrenomedullin
Clinical Status: Inactive
Latest Update: 2024-05-04
Latest Update Note: PubMed Publication

Product Description

Adrenomedullin is a 52 aa peptide with several functions, including vasodilation, regulation of hormone secretion, promotion of angiogenesis, and antimicrobial activity.  (Sourced from: https://www.ncbi.nlm.nih.gov/gene/133)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: University of Miyazaki
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: CADASIL|Colitis, Ulcerative|Dementia, Multi-Infarct|Crohn Disease

Phase 1: Healthy Volunteers|Colitis, Ulcerative|Crohn Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

AML2220

N/A

Unknown status

Acute Myeloid Leukemia

2024-06-01

2024-11-02

Primary Endpoints

H-18020494

N/A

Completed

Migraine Disorders|Headache Disorders

2020-01-30

2020-03-12

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments

ChiCTR-IPR-16007847

N/A

Not yet recruiting

Oxidative Stress|Hypoxia|Acute Respiratory Distress Syndrome|Cardiac Output, High|Acute Lung Injury|Cardiac Output, Low|Reperfusion Injury

2016-03-01

CEP1781/07

N/A

Withdrawn

Heart Failure

2010-12-01

2019-03-19

Treatments

Adults

P1

Completed

Crohn Disease|Colitis, Ulcerative

2022-12-19

2023-02-02

JapicCTI-194890

P1

Completed

Healthy Volunteers

2016-11-30

JapicCTI-194891

P1

Completed

Healthy Volunteers

2016-03-31

AMCAD

P2

Completed

CADASIL|Dementia, Multi-Infarct

2023-01-23

2023-10-11

Primary Endpoints|Treatments

JapicCTI-183947

P2

Unknown

Crohn Disease

2020-03-31

JapicCTI-205255

P2

Unknown

Colitis, Ulcerative

2019-05-31